Invivyd, Inc. (IVVD)

Market Cap	211.72M
Revenue (ttm)	11.56M
Net Income (ttm)	-225.14M
Shares Out	119.62M
EPS (ttm)	-1.94
PE Ratio	n/a
Forward PE	179.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,505,402
Open	1.260
Previous Close	1.210
Day's Range	1.250 - 2.090
52-Week Range	0.355 - 4.740
Beta	0.61
Analysts	Strong Buy
Price Target	7.89 (+345.76%)
Earnings Date	Mar 27, 2025

About IVVD

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in precl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 6, 2021
• Employees: 95
• Stock Exchange: NASDAQ
• Ticker Symbol: IVVD
• Website: https://invivyd.com

Analyst Forecast

According to 4 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price forecast is $7.89, which is an increase of 345.76% from the latest price.

Price Target

$7.89

(345.76% upside)

Analyst Consensus: Strong Buy